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Alzheimer’s disease (AD), a common neurodegenerative disorder associated with gradually to dramatic neuronal
death, synaptic loss and dementia, is considered to be one of the most obscure and intractable brain disorders in
medicine. Currently, there is no therapy clinically available to induce marked symptomatic relief in AD patients. In
recent years, the proof-of-concept studies using stem cell-based approaches in transgenic AD animal models provide
new hope to develop stem cell-based therapies for the effective treatment of AD. The degeneration of basal forebrain
cholinergic neurons (BFCNs) and the resultant cholinergic abnormalities in the brain contribute substantially to the
cognitive decline of AD patients. The approches using stem cell-derived BFCNs as donor cells need to be developed,
and to provide proof of principle that this subtype-specific neurons can induce functional recovery of AD animal
models. With the continuous scientific advances in both academic and industrial fields, the potentials of stem cells in
cellular neuroprotection and cell replacement in vivo have been elucidated, and stem cell-based therapy for repairing
degenerative brains of AD is promising.
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Embryonic stem cellsAlzheimer’s disease (AD), a multifactorial syndrome, is
believed to be the most common form of neurodegener-
ative dementia. Previous studies have demonstrated that
AD is associated with several distinct neuropathological
features, mainly as extracellular Aβ plaques, intracellular
neurofibrillary tangles and neuron lost. Currently, there is
no effective therapies available for the treatment of AD,
and the widely used medicine, including cholinesterase
inhibitors, have very modest clinical effects in treating the
symptoms of AD, such as language loss, cognitive deficits
and behavioral impairments. It was concluded that AD
epitomized the mechanistic ignorance and therapeutic
nihilism that pervaded the study of neurodegeneration in
humans [1]. In 2000, approximately 4.5 million people suf-
fered from AD in the America, which is expected to 13.2
million by the year 2050 [2]. The AD patients by no means
will become one of the largest public health challenges
and place heavy demands on the health care system.* Correspondence: njing@sibcb.ac.cn
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unless otherwise stated.The stem cells hold potentials to develop cell replace-
ment therapies for various neurodegerative disease, in-
cluding AD. The subtype-specific neurons from stem
cells might be the most ideal donor cells to replace the
same type of neurons lost through disease. The embryo
stem cell (ESC)-derived dopaminergic neurons were
shown to correct functional deficits in animal models of
Parkinson’s disease [3,4]. The attempts to develop stem
cell-based therapies for AD have used several types of
cells in AD animal models, such as adult neural stem
cells [5], ESC-derived neural precursor cells [6], a couple
of mesenchymal stem cells [7,8], and astrocytes [9].
These studies had demonstrated that transplanted cells
partially rescue the cognitive deficits of AD animals.
Among the widespread neuron and synaptic loss in AD
brain, the degeneration of basal forebrain cholinergic
neurons (BFCNs) and severe devastation of basal fore-
brain cholinergic innervation of cerebral cortex and
hippocampus in the brain of AD patients are thought to
play essential role in memory impairment, cognitive defi-
cits, and finally lead to dementia [10,11]. The replacement
procedures using stem cell-derived BFCNs as donor cellsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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BFCN needs to be determined.
The purpose of this short review is to briefly summarize
the continuous advances in the development of stem cell-
based approaches for AD in both academic and industrial
fields, and carefully predict the promising potentials of
stem cells for repairing degenerative brains of AD.
The scientific advances in academic research
Recently, multiple attempts have used different types of
stem cells as donor cells and investigated the effects of
stem cell transplantation on relieving neuropathological
symptoms and restoring cognitive function of transgenic
AD animal models. Both cultured adult and neonatal
mouse astrocytes are transplanted into the hippocampus
of ApdE9 AD mice. Seven days later, these astrocytes are
found mainly near Aβ deposits and internalize human
Aβ immunoreactive material in vivo. This study supports
the role of astrocytes as active Aβ clearing cells in the
brain, which may have important implications for future
development of therapeutic strategies for AD [9]. Adult
neural stem cells from newborn GFP transgenic mice
have been transplanted into the hippocampus of aged
3xTg-AD mice, a model that recapitulates many of the
salient features of AD. The neural stem cell transplant-
ation induces a robust enhancement of BDNF-mediated
hippocampal synaptic density and rescues the spatial
learning and memory deficits of AD mice, without altering
Aβ deposits. This study suggests that modulation of
neurotrophin levels could provide a viable approach in the
development of stem cell-based therapies to treat AD in
future [5]. The human umbilical cord blood-derived mes-
enchymal stem cells are transplanted into hippocampus of
AD mice, which rescues memory deficits of host mice by
reducing neuronal apoptosis [7]. The bone marrow-
derived mesenchymal stem cells are transplanted into
hippocampus of AD mice, which reduces Aβ deposits and
rescues memory deficits of host mice [8]. The mouseTable 1 The reported stem cell-based therapies in AD animal
Donor cells AD models Gra
Mouse astrocytes ApdE9 transgeneic mouse Hip
Mouse adult NSCs 3xTg transgeneic mouse Hip
Mouse cholinergic motor
neuron precursors
Rat with NBM lesion NBM
Human UCB-MSCs Not known Hip
Mouse BM-MSCs APP/PS1 transgeneic
mouse
Hip





NSCs, neural stem cells, NBM, nucleus basalis of Meynert, UCB-MSCs, umbilical cord
mesenchymal stem cells, PDAPP, PDGF promoter driven amyloid precursor proteinembryonic stem cell-derived cholinergic motor neuron
precursors are transplanted into the right NBM of rats
with unilateral NBM lesion and memory deficits, and pro-
mote the memory recovery of host rats [6]. The human
iPSC-derived neuronal precursors from SHH/RA treat-
ment are transplanted into the hippocampus of AD trans-
genic mice and restore spatial memory of AD mice [12].
In summary, different types of donor cells that are trans-
planted mainly into hippocampus of AD model animals
exhibit distinct effect on neuropathological symptoms
relief and cognitive function restoration (Table 1). All
these studies suggest the perspective possibility of using
stem cells to develop therapeutics for AD.
The promising application of basal forebrain
cholinergic neurons (BFCNs) in stem cell-based
treatment of AD
There are two major types of cholinergic neurons in the
brain, the projection neurons in the basal forebrain,
known as BFCNs, and interneurons in the striatum. In ro-
dent brain, BFCNs originating in the most ventral regions
of the developing telencephalon at embryonic day 11,
display highly discrete locations and possess striking ana-
tomic heterogeneities [13]. In primate brain, the BFCNs
situate in the medial septal nucleus, vertical limb of the
diagonal band of Broca and nucleus basalis of Meynert
(NBM), and typically innervate all parts of cerebral cortex,
hippocampus, entorhinal cortex and amygdala [14]. The
BFCNs play essential roles in various aspects of cognitive
function, such as learning, memory and attention, and the
cholinergic blockade disrupts the cognitive function of
normal humans [10,15,16]. Numerous studies show the
severe devastation of basal forebrain cholinergic innerv-
ation and resultant declined cholinergic neurotransmis-
sion in the brains of AD patients, and even in the early
stage of AD patients [17–20]. Also, the most severely
affected areas in AD brain are within the temporal lobes,
especially within the hippocampus and entorhinal cortexmodels
ft site Behavior recovery Possible mechanism Key refs.




memory recovery Not Known [6]
pocampus Memory Reducing neuronal
apoptosis
[7]
pocampus Memory reducing Aβ deposits ([8]
pocampus Spatial Memory Not Known [12]
blood-derived mesenchymal stem cells, BM-MSCs, bone marrow-derived
transgenic mice.
Table 2 The advantages and disadvantages of using
BFCNs as donor cells in the stem cell-based approaches
for AD
Advantages Disadvantages
Subtype-specific replacing the lost
endogenous BFCNs in basal
forebrain
The standard preparation of
homogeneous human BFCN
progenitors
Repairing the dysfunctions of basal
forebrain cholinergic system by
releasing acetylcholine,
neurotrophic factors or cytokines
The efficient cholinergic
specificaiton of BFCN progenitors,
and long term survival of
cholinergic derivatives in vivo
Functionally integrating into the
endogenous basal forebrain neural
circuitries
The disabilities of lone-distance in
nervation from the basal forebrain
to hippocampus and cortex
Rescuing the innervation track
along the host cholinergic
projections through out the
basal forebrain
The uneven and patchy migration
through the basal forebrain to
hippocampus and cortex
Yue and Jing Translational Neurodegeneration  (2015) 4:8 Page 3 of 5[21,22]. These studies point out that the degeneration of
BFCNs essentially contribute to the cognitive deficits and
pathogenesis of AD, suggesting that BFCNs might be an
ideal type of donor cells to ameliorate the cognitive symp-
toms associated with AD. Even if the hypothesis by using
BFCNs as donor cells for treating AD is exciting, none of
the studies listed above has attempted to test if BFCNs
can restore cholinergic function and alleviate cognitive
deficits in AD model animals. Indeed, BFCNs cannot be
stably generated from pluripotent stem cells, either mouse
or human embryonic stem cells (ESCs) for the transplant-
ation experiments. Up to date, the optimal strategy direct-
ing the differentiation of pluripotent stem cells into
BFCNs in vitro has not been established, which is mainly
due to the unclear molecular basis of the differentiation
and development of BFCNs in vivo. A number of
endogenous neurotrophic factors, such as nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF),
basic fibroblast growth factor (bFGF) and bone morpho-
genetic protein 9 (BMP9), have been reported to partici-
pate and promote the survival, growth, and differentiation
of cholinergic neurons, and probably BFCNs in the brain
[23–25]. The various transcription factors, such as Mash1,
Islet1, Nkx2.1, Lhx8, and Olig2, act hierarchically to deter-
mine the cell fate and function coordinately to maintain
the cell identity of striatal cholinergic neurons, but the
dynamics expression and genetic determinants of these
factors in the development of BFCNs are incompletely
understood [26–29].
Due to the unclear elucidation of key developmental
factors and extracellular signals that control the develop-
ment of BFCNs in vivo, the successful derivation of
BFCNs from mouse ESCs has not been reported, and
the studies on differentiation of human ESCs to BFCNs
has been sparse. Few years ago, Bissonnette and col-
leagues [30] reported the derivation of a predominantly
pure BFCN population from human ESCs. They used
diffusible ligands present in forebrain, including RA in
the early stage of neural induction in their method.
These human ESC-derived BFCN neurons express
typical cholinergic neuronal markers, and stably and
functionally engraft in murine ex vivo hippocampal
slices through generating electrophysiologically func-
tional cholinergic synapses and firing action potentials.
Two years later, Liu and colleagues have developed a
method for differentiating hESCs to a nearly homoge-
neous population of MGE-like progenitors [31]. Following
their differentiation protocols, these MGE-like progenitors
finally give rise to mixed cell population containing nearly
equal amount of GABAergic interneurons and BFCNs.
After transplantation into the hippocampus of severe
combined immunodeficiency (SCID) mice in which
BFCNs and some GABA neurons in the medial septum
had been destroyed by muP75-saporin, human MGE-likeprogenitors produced BFCNs that synaptically connected
with endogenous neurons. More excitingly, mice trans-
planted with MGE-like progenitors showed improvements
in learning and memory deficits. The function of ESC-
derived BFCNs has been tested from the murine ex vivo
hippocampal slices to the severe combined immunodefi-
ciency mice with medial septum lesion, indicating that
one step has moved forward on the road of exploring the
subtype-specific neuron-based cell therapy for AD. Re-
cently, we have successfully differentiated both mouse and
human ESCs into BFCNs through a highly pure popula-
tion of BFCN progenitors. Both mouse and human ESC-
derived BFCN progenitors are transplanted into the NBM
of transgenic AD model mice, 5XFAD and APP/PS1, and
specifically differentiated into mature and functional
cholinergic neurons in vivo. These exogenous cholinergic
neurons exhibited typical basal forebrain cholinergic pro-
jection and migration patterns, and morphologically and
functionally incorporate into the endogenous projection
system. Importantly, AD mice with transplanted BFCN
progenitors exhibited improved learning and referenced
memory abilities in the behavior test, demonstrating the
feasibility of using ESC-derived BFCNs for the develop-
ment of stem cell therapy for AD (unpublished data).
It is well accepted that the degeneration of BFCNs and
resultant devastation cholinergic innervation spread a
large area of brain, from basal forebrain to hippocampus
and entorhinal cortex in temporal lobe. However, the
time that BFCNs start to degenerate through disease
processing remains unclear, and mechanism underlying
the BFCN degeneration needs to be elucidated. These
unknown events make it more difficult to optimize the
cell replacement procedures using BFCNs. The optimal
transplantation site remains to be determined. The sur-
vival, proliferation, cell fate specification and differentiation
of grafted BFCN progenitors need to be fine controlled.
The biochemical functions, migration, projection and
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Obviously, the procedures of stem cell therapies using
ESC-derived BFCNs for the treatment of AD are far from
optimal, and the challenges ahead will be tremendous
(Table 2).The translational perspective in stem-cell based
therapy of AD in industry
Even with the continuous progress in developing stem
cell-based therapy for AD in academic field, the challenges
in the early stage of stem-cell based therapy to treat
neurodegeneratice diease, including AD, are obviously
insurmountable. However, the transition from proof-of-
concept studies in AD animals to human clinical trials in
AD patients has already been underway in the industrial
field, which comes sooner than one might think [32]. In
1999, based on their groundbreaking finding of cell sur-
face markers for adult human neural stem cell, the scien-
tists of StemCells Inc. have successfully isolated a highly
purified, expandable population of neural stem cells from
human brain tissue by using monoclonal antibodies
against the cell surface markers. Then, the human neural
stem cells have been prepared under controlled conditions
and cGMP standards and named HuCNS-SC cells. The
rigorous preclinical studies have shown that HuCNS-SC
cells can survive long-term with no evidence of tumor
formation or adverse effects, and engraft, migrate, differ-
entiate into neurons, astrocytes and oligodendrocytes. In
2011, StemCells established collaborations with some
famous AD research groups in the world to study the
therapeutic potential of HuCNS-SC cells in AD. The pre-
liminary results showed HuCNS-SC cells can survive in
brain of AD animal models, and StemCells Inc. hopes to
advance toward clinical testing of HuCNS-SC cells in AD
patients. Different from StemCell, the NeuralStem has
devoted to isolate and expand regionally specific cells.
NeuralStem has announced their preclinical study by
using engineered human cortex-derived neural stem cells
for AD. The neural stem cells can secrete human insulin-
like growth factor 1 and rescue spatial learning and mem-
ory deficits after transplanted into an animal model of AD.
Although the stem cell-based therapy for AD has com-
menced, it is still in the earlier stage compared to develop-
ment of stem cell therapy candidates and technological
platforms for other brain or spinal cord disorders. The
clinical trial of human ESC-derived oligodendrocyte pro-
genitors from Geron for spinal cord injury has been
authorized by FDA, which is a milestone for the stem cell
therapy field. The clinical-grade neural stem cell CTX
from ReNeuron has been appoved for the phase II clinical
trials for treatment of stroke. With the continued progress
and mutual involvement of scientific, ethical, regulatory,
translational and clinical fields, more and more companiesstart to involve in and make efforts to develop rational
stem cell-based therapies for the treatment of AD.
The progresses in both scientific and industrial fields
have provided proof of principle that the stem cells can
induce marked improvements in AD animals, and may
lead to valuable improvement in clinical trials. But,
there are still different kinds of challenges ahead before
stem cell-based therapy can move to the clinic as a
treatment for AD: a) the standard preparation of cells
suitable for transplantation has not been achieved, b)
the present cell replacement procedures are far from
optimal, c) it is still unclear the mechanism underlying
symptomatic relief upon cell transplantation, d) it still
needs to be determined the chronic inflammatory and
immune response due to the cell grafts. Even though,
the continued understanding in cell biology of donor
cells, the advances in stem cell transplantation and
involvement of clinical activities will facilitate the de-
velopment of stem cell-based therapeutic strategies for
AD, and the perspective of stem cell therapy for the
treatment of AD is expected.
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